{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:59:05Z","timestamp":1790632745851,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10792-020-01479-1","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T02:03:37Z","timestamp":1594001017000},"page":"2957-2967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of mineralocorticoid receptor antagonist for central serous chorioretinopathy: a meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Bilei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-5058","authenticated-orcid":false,"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"issue":"1","key":"1479_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"2008","unstructured":"Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002. Ophthalmology 115(1):169\u2013173","journal-title":"Ophthalmology"},{"issue":"6","key":"1479_CR2","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/IAE.0000000000002092","volume":"39","author":"J Yu","year":"2019","unstructured":"Yu J, Jiang C, Xu G (2019) Correlations between changes in photoreceptor layer and other clinical characteristics in central serous chorioretinopathy. Retina 39(6):1110\u20131116","journal-title":"Retina"},{"issue":"2","key":"1479_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1442-9071.2012.02848.x","volume":"41","author":"G Liew","year":"2013","unstructured":"Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41(2):201\u2013214","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"1479_CR4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41433-019-0381-7","volume":"33","author":"F Sartini","year":"2019","unstructured":"Sartini F, Figus M, Nardi M, Casini G, Posarelli C (2019) Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye (Lond) 33(7):1035\u20131043","journal-title":"Eye (Lond)"},{"issue":"1","key":"1479_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2017.06.008","volume":"63","author":"BP Nicholson","year":"2018","unstructured":"Nicholson BP, Atchison E, Idris AA, Bakri SJ (2018) Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol 63(1):1\u20138","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"1479_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0002-9394(14)70531-8","volume":"121","author":"C Prunte","year":"1996","unstructured":"Prunte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121(1):26\u201334","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1479_CR7","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M et al (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122(7):2672\u20132679","journal-title":"J Clin Invest"},{"key":"1479_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82\u2013118","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"1479_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3928\/23258160-20180628-03","volume":"49","author":"B Rajesh","year":"2018","unstructured":"Rajesh B, Agrawal H, Peguda HK, Chhablani J (2018) Predictors of outcome during eplerenone therapy in chronic central serous chorioretinopathy: a prospective, Open-Label pilot clinical study. Ophthalmic Surg Lasers Imaging Retina 49(7):479\u2013486","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"4","key":"1479_CR10","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/eye.2017.295","volume":"32","author":"R Sacconi","year":"2018","unstructured":"Sacconi R, Baldin G, Carnevali A, Querques L, Rabiolo A, Marchini G et al (2018) Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. Eye (Lond) 32(4):734\u2013742","journal-title":"Eye (Lond)"},{"issue":"6","key":"1479_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/IAE.0000000000001303","volume":"37","author":"R Gergely","year":"2017","unstructured":"Gergely R, Kovacs I, Schneider M, Resch M, Papp A, Recsan Z et al (2017) Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina 37(6):1084\u20131091","journal-title":"Retina"},{"issue":"2","key":"1479_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00417-016-3436-5","volume":"255","author":"TR Herold","year":"2017","unstructured":"Herold TR, Rist K, Priglinger SG, Ulbig MW, Wolf A (2017) Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). Graefes Arch Clin Exp Ophthalmol 255(2):221\u2013229","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"1479_CR13","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00417-016-3373-3","volume":"254","author":"B Cakir","year":"2016","unstructured":"Cakir B, Fischer F, Ehlken C, Buhler A, Stahl A, Schlunck G et al (2016) Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254(11):2151\u20132157","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"1479_CR14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006\u20131012","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"1479_CR15","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","volume":"35","author":"E Bousquet","year":"2015","unstructured":"Bousquet E, Beydoun T, Rothschild PR, Bergin C, Zhao M, Batista R et al (2015) Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina 35(12):2505\u20132515","journal-title":"Retina"},{"issue":"2","key":"1479_CR16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","volume":"135","author":"RW Beck","year":"2003","unstructured":"Beck RW, Moke PS, Turpin AH, Ferris FR, SanGiovanni JP, Johnson CA et al (2003) A computerized method of visual acuity testing: Adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 135(2):194\u2013205","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1479_CR17","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","volume":"38","author":"E Rahimy","year":"2018","unstructured":"Rahimy E, Pitcher JR, Hsu J, Adam MK, Shahlaee A, Samara WA et al (2018) A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior). Retina 38(5):962\u2013969","journal-title":"Retina"},{"issue":"7","key":"1479_CR18","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1111\/aos.13491","volume":"95","author":"R Schwartz","year":"2017","unstructured":"Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S et al (2017) Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol 95(7):e610\u2013e618","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"1479_CR19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/bjophthalmol-2017-311096","volume":"102","author":"X Sun","year":"2018","unstructured":"Sun X, Shuai Y, Fang W, Li J, Ge W, Yuan S et al (2018) Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol 102(8):1060\u20131065","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1479_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/eye.2017.290","volume":"32","author":"A Rabiolo","year":"2018","unstructured":"Rabiolo A, Zucchiatti I, Marchese A, Baldin G, Sacconi R, Montorio D et al (2018) Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy. Eye (Lond) 32(1):55\u201366","journal-title":"Eye (Lond)"},{"issue":"1","key":"1479_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000444058","volume":"56","author":"KG Kapoor","year":"2016","unstructured":"Kapoor KG, Wagner AL (2016) Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis. Ophthalmic Res 56(1):17\u201322","journal-title":"Ophthalmic Res"},{"key":"1479_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002507","author":"DY Kim","year":"2019","unstructured":"Kim DY, Lee JY, Lee EK, Kim JY (2019) Comparison of visual\/anatomical outcomes and recurrence rate between oral spironolactone and photodynamic therapy for nonresolving central serous chorioretinopathy. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000002507 e-pub ahead of print 11 Mar 2019","journal-title":"Retina"},{"issue":"1","key":"1479_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40123-018-0121-2","volume":"7","author":"I Zucchiatti","year":"2018","unstructured":"Zucchiatti I, Sacconi R, Parravano MC, Costanzo E, Querques L, Montorio D et al (2018) Eplerenone versus observation in the treatment of acute central serous chorioretinopathy: a retrospective controlled study. Ophthalmol Ther 7(1):109\u2013118","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1479_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/IAE.0000000000001913","volume":"39","author":"JH Lee","year":"2019","unstructured":"Lee JH, Lee SC, Kim H, Lee CS (2019) Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous chorioretinopathy. Retina 39(1):127\u2013133","journal-title":"Retina"},{"issue":"3","key":"1479_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/jop.2016.0068","volume":"33","author":"A Rubsam","year":"2017","unstructured":"Rubsam A, Thieme CE, Schlomberg J, Winterhalter S, Muller B, Joussen AM et al (2017) Therapy rationale for mineralocorticoid-receptor antagonists, acetazolamide and a switch of therapy in nonresponders in central serous chorioretinopathy. J Ocul Pharmacol Ther 33(3):141\u2013148","journal-title":"J Ocul Pharmacol Ther"},{"issue":"12","key":"1479_CR26","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00417-014-2780-6","volume":"252","author":"TR Herold","year":"2014","unstructured":"Herold TR, Prause K, Wolf A, Mayer WJ, Ulbig MW (2014) Spironolactone in the treatment of central serous chorioretinopathy\u2014a case series. Graefes Arch Clin Exp Ophthalmol 252(12):1985\u20131991","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"1479_CR27","first-page":"1284","volume":"56","author":"P Carrai","year":"2015","unstructured":"Carrai P, Pichi F, Behar-Cohen FF, Ciardella A, Nucci P (2015) Comparison of two mineralocorticoid receptor antagonists in the treatment of central serous chorioretinopathy. Investig Ophthalmol Vis Sci 56(7):1284","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"1479_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jamaophthalmol.2014.5312","volume":"133","author":"M Zhao","year":"2015","unstructured":"Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C et al (2015) A 50% versus 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. Jama Ophthalmol 133(3):333\u2013340","journal-title":"Jama Ophthalmol"},{"issue":"2","key":"1479_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/IAE.0000000000001138","volume":"37","author":"CK Cheng","year":"2017","unstructured":"Cheng CK, Chang CK, Peng CH (2017) Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 37(2):325\u2013333","journal-title":"Retina"},{"issue":"10","key":"1479_CR30","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/IAE.0000000000002294","volume":"38","author":"Y Sakurada","year":"2018","unstructured":"Sakurada Y, Leong B, Parikh R, Fragiotta S, Freund KB (2018) Association between choroidal caverns and choroidal vascular hyperpermeability in eyes with pachychoroid diseases. Retina 38(10):1977\u20131983","journal-title":"Retina"},{"issue":"2","key":"1479_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.oret.2018.09.003","volume":"3","author":"SK Wang","year":"2019","unstructured":"Wang SK, Sun P, Tandias RM, Seto BK, Arroyo JG (2019) Mineralocorticoid receptor antagonists in central serous chorioretinopathy: a meta-analysis of randomized controlled trials. Ophthalmol Retina 3(2):154\u2013160","journal-title":"Ophthalmol Retina"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01479-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-020-01479-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01479-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T19:23:12Z","timestamp":1625512992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-020-01479-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01479-1","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"7 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}